SNORA31: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: SNORA31

NCBI ID: G677814

SNORA31

Other Name(s): ACA31 | IIAE10 | Small nucleolar RNA, H/ACA box 31 | SNORA31A | small nucleolar RNA, H/ACA box 31

SNORA31: A Potential Drug Target for Cancer and Neurodegenerative Diseases

SNORA31 (ACA31) is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, and kidneys. It is a member of theSnor family, which includes several other proteins that are involved in a variety of cellular processes , including cell signaling, DNA replication, and metabolism.

Recent studies have identified SNORA31 as a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because SNORA31 is involved in several cellular processes that are disrupted in these conditions, and because it is a protein that is expressed in high levels in many tissues, making it an attractive target for drug developers.

One of the reasons why SNORA31 is considered a potential drug target is because it is involved in several signaling pathways that are involved in the development and progression of many diseases. For example, SNORA31 is involved in the TGF-β pathway, which is a well -established pathway for the development of cancer. In addition, SNORA31 is involved in the Wnt pathway, which is involved in the development and maintenance of tissues and organs.

Another reason why SNORA31 is considered a potential drug target is because it is a protein that is expressed in high levels in many tissues, which makes it an attractive target for drug developers because it is easier to recruit to drug targets. Additionally, SNORA31 is a small protein, which makes it easier to synthesize and purify for use in experiments.

In addition to its involvement in signaling pathways, SNORA31 is also involved in several cellular processes that are important for the proper functioning of tissues and organs. For example, SNORA31 is involved in the regulation of cell growth and in the production of certain signaling molecules, such as TGF-β1. In addition, SNORA31 is involved in the regulation of inflammation, which is important for the immune response and for the regulation of many diseases.

Recent studies have also identified SNORA31 as a potential biomarker for several diseases. For example, SNORA31 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In addition, SNORA31 has been shown to be involved in the development of cancer, including breast and ovarian cancer.

Despite these promising findings, more research is needed to fully understand the role of SNORA31 in diseases and to identify potential drug targets. Many researchers are currently working to synthesize and study SNORA31, in order to understand its role in diseases and to identify potential drug targets..

In conclusion, SNORA31 is a protein that is expressed in various tissues throughout the body and is involved in several cellular processes that are important for the proper functioning of tissues and organs. Recent studies have identified SNORA31 as a potential drug target for several diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand the role of SNORA31 in diseases and to identify potential drug targets.

Protein Name: Small Nucleolar RNA, H/ACA Box 31

The "SNORA31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets